We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.41B
AUM Growth
-$143M
Cap. Flow
+$78.9M
Cap. Flow %
5.61%
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
2
FOLD
Amicus Therapeutics
FOLD
+$22M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$21.2M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.7M
5
ANIP icon
ANI Pharmaceuticals
ANIP
+$15.6M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$25.1M
2
DXCM icon
DexCom
DXCM
+$15.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$13.5M
4
ASRT
Assertio
ASRT
+$13.4M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Miscellaneous 1.6%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLPH icon
26
Talphera
TLPH
$61.8M
$14.1M 1%
270,436
– –
QTNT
27
DELISTED
Quotient Limited Ordinary Shares
QTNT
$13.8M 0.98%
71,362
+4,567
+7% +$988K
ACOR
28
DELISTED
Acorda Therapeutics
ACOR
$13.5M 0.96%
+6,000
New +$14.3M
ZYNE
29
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$13.1M 0.93%
842,128
-26,769
-3% -$361K
KDMN
30
DELISTED
Kadmon Holdings, Inc.
KDMN
$11.8M 0.84%
2,209,657
– –
IRTC icon
31
iRhythm Holdings
IRTC
$3.69B
$10.6M 0.75%
+352,241
New +$9.49M
CRBP icon
32
Corbus Pharmaceuticals
CRBP
$134M
$10.6M 0.75%
41,667
-48,367
-54% -$11.1M
ALDX icon
33
Aldeyra Therapeutics
ALDX
$82.6M
$10.4M 0.74%
1,940,458
– –
CTMX icon
34
CytomX Therapeutics
CTMX
$586M
$10.2M 0.72%
+923,763
New +$11.2M
RDUS
35
DELISTED
Radius Health, Inc.
RDUS
$10M 0.71%
263,872
-49,630
-16% -$2.36M
DERM
36
DELISTED
Dermira, Inc.
DERM
$9.88M 0.7%
325,583
-6,027
-2% -$194K
NERV icon
37
Minerva Neurosciences
NERV
$183M
$9.52M 0.68%
101,317
– –
ZGNX
38
DELISTED
Zogenix, Inc.
ZGNX
$9.15M 0.65%
752,999
+734,458
+3,961% +$8.07M
ASMB icon
39
Assembly Biosciences
ASMB
$532M
$8.68M 0.62%
59,530
-5,276
-8% -$785K
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.09B
$8.42M 0.6%
+1,330,240
New +$6.92M
PFNX
41
DELISTED
Pfenex Inc.
PFNX
$8.29M 0.59%
914,376
-25,554
-3% -$233K
FPRX
42
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$8.18M 0.58%
163,255
-3,254
-2% -$171K
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.09M 0.58%
624,694
-10,200
-2% -$157K
CDTX
44
DELISTED
Cidara Therapeutics
CDTX
$8.04M 0.57%
38,668
– –
ALDR
45
DELISTED
Alder Biopharmaceuticals
ALDR
$7.99M 0.57%
384,169
-7,111
-2% -$185K
BPMC
46
DELISTED
Blueprint Medicines
BPMC
$7.68M 0.55%
273,820
-186,204
-40% -$5.61M
CLVS
47
DELISTED
Clovis Oncology, Inc.
CLVS
$7.45M 0.53%
167,754
-3,746
-2% -$132K
QURE icon
48
uniQure
QURE
$2.99B
$7.09M 0.5%
1,265,963
-46,873
-4% -$315K
ATRS
49
DELISTED
Antares Pharma, Inc.
ATRS
$6.8M 0.48%
+2,917,253
New +$5.55M
CLSD
50
DELISTED
Clearside Biomedical
CLSD
$6.37M 0.45%
47,471
+5,151
+12% +$1.29M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $78.9M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.

  • Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
  • Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
  • Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
  • Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
  • Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.

Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.